Owlstone Ltd
14
3
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
1 terminated/withdrawn out of 14 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis
Role: lead
Single Dose Texas 2017 (H3N2) Challenge Study
Role: collaborator
Diagnostic Accuracy Study for OWL-EVO1 As a Lung Cancer EVOC® Probe (Evolution Phase 2)
Role: lead
Early Liver Disease Breath Detection
Role: lead
Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients
Role: lead
Wessex Asthma Cohort of Difficult Asthma
Role: collaborator
Safety and Dose Ranging Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution)
Role: lead
PAN-study: Pan-Cancer Early Detection Study (PAN)
Role: lead
Lung Cancer Indicator Detection
Role: lead
Mesothelioma Early Detection by VOCs
Role: collaborator
Metabolomics in Occupational Asthma
Role: collaborator
Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study
Role: lead
Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols
Role: lead
Exhaled Breath Metabolomic Biomarkers in the Acutely Breathless Patient
Role: collaborator
All 14 trials loaded